NR ARER
AU Schwarz,A.; Burwinkel,M.; Riemer,C.; Bamme,T.; Mok,S.W.F.; Baier,M.
TI Therapy of prion infections in a murine model system
QU TSE-Forum, 4. Kongress - Nationale TSE-Forschungsplattform, Düsseldorf 28.10.-29.10.2004, Poster THE-01
PT Konferenz-Poster
AB
Transmissible spongiform encephalopathies are ultimately lethal progressive neurodegenerative disorders usually linked to the appearance of an abnormal insoluble and protease-resistant form of a normal host-encoded protein the prion protein (PrP), for which are no cures known. Due to the central role of misfolded prion protein (termed PrPres) in the disease development attempts to identify inhibitors of PrPres aggregation and prion replication address the most obvious target for therapeutic intervention in human TSEs. However, substances, which effectively cured prion-infected cell cultures, were ineffective against prion infections in vivo. The failure of these drugs to show a therapeutic benefit may be due to different folding requirements for generation of PrPres in vivo compared to those in vitro.
Besides targeting prion replication a rational for therapeutic intervention could be to aim at its consequences, namely to address therapeutically chronic inflammatory reactions and neuronal loss in the central nervous system. We report and discuss here the results obtained for the treatment of scrapie-infected mice with minocycline, dapsone, S-ibuprofen, memantine, and an inhibitor of microglia/monocyte differentiation.
AD Anja Schwarz, Michael Burwinkel, Constanze Riemer, Theresa Bamme (Tel: 030-4547-0, E-Mail: bammet@rki.de), Mok Wang Fai Simon, Michael Baier (Tel: 030-4547-0, E-Mail: baierm@rki.de), Robert-Koch-Institut, Nordufer 20, 13353 Berlin
SP englisch
PO Deutschland
OR Tagungsband